

平成29年度橋渡し研究戦略的推進プログラムの 成果活用支援事業の実績報告 ポートフォリオマネジメント

西村 秀雄 栗田加奈子 菊池 貴幸 山口 頂 福島 雅典

公益財団法人 神戸医療産業都市推進機構 医療イノベーション推進センター

The accomplishment of Japanese TR Centers in 2017 and future prospects

Hideo Nishimura Kanako Kurita Takayuki Kikuchi Itadaki Yamaguchi Masanori Fukushima
Translational Research Center for Medical Innovation,
Foundation for Biomedical Research and Innovation at Kobe

Abstract

14 major Translational and Clinical Research Core Centers (TR Centers) in Japan, including 11 universities and 3 national centers, were found to have 1,260 medical innovation R&D pipelines in the 2017 survey, 45% of which are for unmet needs regarding rare and intractable diseases. This has been clarified as an accomplishment of the national TR-promotion program endorsed by the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, and the Japan Agency for Medical Research and Development (AMED) since 2007 and currently consolidated as the “Project for Translational and Clinical Research Core Centers” within the AMED. Among these pipelines, 121 will apply for approval at the clinical trial stage, and 7 are awaiting approval. 26 approvals have been obtained by regulatory agencies so far, and 154 more approvals are expected by the year 2021. In the near future, TR Centers in Japan are likely to take the global initiative to overcome intractable diseases one by one. This could be achieved by each TR Center becoming a self-sustaining organization, ensuring that each product obtains approval, acquiring substantial profit from pharmaceutical companies by licensing and accumulating it, and increasing self-discretion for innovation development in each TR Center, thus contributing to accelerating medical innovation.

Key words

R&D pipeline, disease-specific portfolio, medical innovation, self-sustainability, interactive disease

Rinsho Hyoka (Clinical Evaluation). 2018 ; 46 : 287-301.